Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma

BACKGROUND: The addition of monoclonal antibody therapy against GD2 to the treatment of high-risk neuroblastoma led to improved responses in patients. Nevertheless, administration of GD2 antibodies against neuroblastoma is associated with therapy-limiting neuropathic pain. This severe pain is evoked...

Descripción completa

Detalles Bibliográficos
Autores principales: Evers, Mitchell, Stip, Marjolein, Keller, Kaylee, Willemen, Hanneke, Nederend, Maaike, Jansen, Marco, Chan, Chilam, Budding, Kevin, Nierkens, Stefan, Valerius, Thomas, Meyer-Wentrup, Friederike, Eijkelkamp, Niels, Leusen, Jeanette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559241/
https://www.ncbi.nlm.nih.gov/pubmed/34716207
http://dx.doi.org/10.1136/jitc-2021-003163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559241/
https://www.ncbi.nlm.nih.gov/pubmed/34716207
http://dx.doi.org/10.1136/jitc-2021-003163

Ejemplares similares